Med School: Separating Hype from Hope in Genome Science

Genomic discoveries were supposed to transform medicine and move us to a new vision of preventive health care. But 15 years after the Human Genome Project was complete, that still hasn’t happened. Meanwhile, direct-to-consumer genetics companies are bypassing health care providers to market ancestry, disease risk, diet, exercise and even dating and wine applications directly to the public. Robert Green, one of the world’s leaders in generating the evidence-base for genomic medicine, describes what's right and what’s wrong with the genomic revolution, and how we can realize the promise of precision medicine for all.
(Underwritten by America's Biopharmaceutical Companies)

Speakers: Robert C. Green
Festival: Spotlight Health 2018

Watch and Listen: Health

Larry Smarr believes in being the CEO of his own body, and for years, he has been measuring inputs (food and drink) and... See more
Once associated mostly with IV poles and standard-issue hospital gowns, health-related design has entered a new era... See more
Despite repeated attempts, Congress has not repealed the Affordable Care Act, although the Trump Administration has... See more
The Affordable Care Act became law because five congressional leaders made it happen. These committee chairs — two from... See more
Despite all of the scientific advances in genomic sequencing, genetic testing, and gene editing, science writer Carl... See more
Whether the headlines describe a “cancer moonshot” or a “war on cancer,” they capture a yearning and determination to... See more

Pages